Updates are available Correction dated 2025-09-07
Click to view Correction: https://doi.org/10.1038/s41392-025-02379-5
-
Authors
Zhou, Xuantong
Huang, Furong
Ma, Gang
Wei, Wenqing
Wu, Nan https://orcid.org/0000-0002-3531-1656
Liu, Zhihua https://orcid.org/0000-0003-4242-033X
- License Information
-
More Information
Article History
Received: 19 January 2022
Revised: 16 August 2022
Accepted: 19 September 2022
First Online: 24 October 2022
Change Date: 2 September 2025
Change Type: Update
Change Details: The original online version of this article was revised: Fig. 6g and Supplementary Fig. S5f, and S10c replaced with correct version.
Change Date: 7 September 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41392-025-02379-5
Competing interests
: The authors declare no competing interests.
: A commercial human ESCC tissue microarray was purchased from Outdo Biotech Company (#HEso-Squ150CS-02, Shanghai, China). Additionally, human ESCC tissue samples were obtained from patients receiving operations at Zhejiang Cancer Hospital (Hangzhou, China). All patients did not undergo neoadjuvant therapy. Informed consent was obtained from each enrolled patient. All human specimens were used in IHC experiments. This study was approved by the ethical committee of Chinese Academy of Medical Sciences Cancer Hospital (Beijing, China). Six-week-old male SCID/Beige mice were purchased from Vital River Laboratories (Beijing, China). All mice used in this study were housed under specific pathogen-free (SPF) conditions. All procedures and experimental protocols were approved by the Institutional Animal Care and Use Committee of Chinese Academy of Medical Sciences Cancer Hospital (Beijing, China).
